Seres Therapeutics (NASDAQ:MCRB) Share Price Passes Below 50-Day Moving Average – Time to Sell?

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $8.13 and traded as low as $6.62. Seres Therapeutics shares last traded at $6.85, with a volume of 132,707 shares traded.

Analyst Ratings Changes

A number of research firms have weighed in on MCRB. Canaccord Genuity Group reiterated a “buy” rating and set a $22.00 target price on shares of Seres Therapeutics in a report on Friday, March 13th. Wall Street Zen upgraded Seres Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings downgraded Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 18th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $22.00.

Seres Therapeutics Price Performance

The stock’s 50 day simple moving average is $8.08 and its two-hundred day simple moving average is $11.82. The firm has a market cap of $64.18 million, a P/E ratio of -1.28 and a beta of 0.13.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The company had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.36 million.

Institutional Investors Weigh In On Seres Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. bought a new stake in shares of Seres Therapeutics during the fourth quarter valued at approximately $213,000. Invesco Ltd. grew its position in Seres Therapeutics by 37.5% in the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 3,918 shares during the period. OMERS ADMINISTRATION Corp bought a new stake in Seres Therapeutics in the 4th quarter worth approximately $214,000. Marshall Wace LLP bought a new stake in Seres Therapeutics in the 2nd quarter worth approximately $1,016,000. Finally, Geode Capital Management LLC grew its position in Seres Therapeutics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after purchasing an additional 1,160 shares during the period. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.